EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry

Lisa P van der Rijst, Chantal M van Luijk, Sara van der Kamp, Nicolaas P A Zuithoff, Joke H de Boer, Marjolein S de Bruin-Weller, Marlies de Graaf iD

Clinical & Experimental Allergy · 2025

DOI: 10.1111/cea.70025 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2025. Written by Lisa P van der Rijst and 6 co-authors. Institution: Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Dermatology and Allergolo…. Major MEDLINE topics: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Cited 12 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Dupilumab‐associated ocular surface disease (DAOSD) is a common side effect in paediatric atopic dermatitis (AD) patients treated with dupilumab. However, long‐term real‐world safety data is limited. Therefore, this study investigates the incidence of DAOSD in paediatric AD patients treated with dupilumab and identifies associated risk factors.

Methods

This prospective study included paediatric AD patients (aged 3–17 years) treated with dupilumab. Ocular symptoms were assessed every 4–12 weeks. DAOSD was initially treated with lubricating eye drops, antihistamine eye drops, and/or tacrolimus ointment for the external eyelids. Persistent symptoms were treated with ocular anti‐inflammatory therapy. Ophthalmological examination was performed in patients with DAOSD requiring ocular anti‐inflammatory therapy. Univariable and multivariable regression analyses were conducted to identify predictors for developing DAOSD.

Results

A total of 104 patients (11.7 ± 4.0 years) with a median follow‐up of 70.5 weeks were included. Overall, 34.6% (36/104) of patients developed DAOSD, of which 30.6% (11/36) required ocular anti‐inflammatory therapy. The development of DAOSD was not age‐dependent, nor was it associated with pre‐existing allergic conjunctivitis. The most common ocular symptoms were pruritus (75.0%), redness (72.2%), and tearing (58.3%). Ophthalmological examination revealed tarsal conjunctivitis in all patients with DAOSD requiring ocular anti‐inflammatory therapy. Baseline serum IgE levels of ≥ 3000 kU/L were independently associated with the development of DAOSD (OR 4.65; 95% CI 1.43–15.11, p = 0.011). DAOSD led to dupilumab discontinuation in 3.8% (4/104) of patients.

Conclusions

This prospective, long‐term, real‐world study shows that 34.6% of paediatric AD patients treated with dupilumab develop DAOSD. Elevated baseline serum IgE (≥ 3000 kU/L) may predict the development of DAOSD. The high incidence of DAOSD underscores the importance of awareness of ocular symptoms during dupilumab treatment, especially in (young) paediatric patients, where reporting ocular symptoms can be challenging and may lead to delayed diagnosis.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansChildMaleFemaleAdolescentChild, PreschoolProspective StudiesRegistriesRisk FactorsIncidence

Author keywords

atopic dermatitischildrenconjunctivitisdupilumabocular surfacepaediatrictype 2 inflammation

Substances

Antibodies, Monoclonal, Humanizeddupilumab

Authors and institutions

  • Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Dermatology and Allergology, Utrecht University, Utrecht, the Netherlands.
  • Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID profiles: Marlies de Graaf

Cite

APA

van der Rijst, L. P., van Luijk, C. M., van der Kamp, S., Zuithoff, N. P. A., de Boer, J. H., de Bruin-Weller, M. S., & de Graaf, M. (2025). Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70025

Vancouver

van der Rijst LP, van Luijk CM, van der Kamp S, Zuithoff NPA, de Boer JH, de Bruin-Weller MS, et al. Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70025

BibTeX
@article{vanderRijst2025,
  author = {van der Rijst, Lisa P and van Luijk, Chantal M and van der Kamp, Sara and Zuithoff, Nicolaas P A and de Boer, Joke H and de Bruin-Weller, Marjolein S and de Graaf, Marlies},
  title = {Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  doi = {10.1111/cea.70025}
}
Start for free →